Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy

Immune checkpoint inhibitors (ICIs) are remarkable breakthroughs in treating various types of cancer, but many patients still do not derive long-term clinical benefits. Increasing evidence shows that TGF-β can promote cancer progression and confer resistance to ICI therapies. Consequently, dual bloc...

Full description

Bibliographic Details
Main Authors: Zhen-Hua Wu, Na Li, Zhang-Zhao Gao, Gang Chen, Lei Nie, Ya-Qiong Zhou, Mei-Zhu Jiang, Yao Chen, Juan Chen, Xiao-Fen Mei, Feng Hu, Hai-Bin Wang
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
cancer immunotherapy
PD-L1
TGF-β
bifunctional fusion protein
BR102
Online Access:https://www.mdpi.com/2072-6694/14/19/4964

Internet

https://www.mdpi.com/2072-6694/14/19/4964

Similar Items